ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis.

A multiple sclerosis patient shares essential guidance from her 13-year diagnostic journey, offering hope and practical tips ...

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

Most MS treatments don't increase the risk for miscarriage or major birth defects when used during pregnancy, an analysis ...

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...

ANK-700 is under clinical development by Anokion and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS).

A new study found that most therapies used to treat multiple sclerosis (MS) were linked to a higher risk of low birth weight. | Neuroscience ...

Many people living with the degenerative neurological disease multiple sclerosis (MS) are premenopausal women. This means ...